innovations from the therapeutics antibody space: obligate bispecific antibodies & t cell engagers
Published 2 years ago • 1.9K plays • Length 1:15:12Download video MP4
Download video MP3
Similar videos
-
30:36
bispecific antibodies to engage vγ9vδ2-t cells for cancer immunotherapy
-
3:00
drawn to science | t-cell bispecific antibodies
-
49:07
a mucin 16 bispecific t cell-engaging antibody for the treatment of ovarian cancer
-
14:00
what are bispecific antibodies?
-
4:01
what are the differences between car t-cell therapy and bispecific antibodies?
-
3:59
bispecific t-cell engagers in the treatment of myeloma
-
4:26
what are bispecific antibodies?
-
1:03:09
developing a portfolio of first-in-class immune-oncology antibodies
-
48:48
antibodies to watch in 2022
-
1:36
bispecific t-cell engagers (bites) as treatment of b-cell lymphoma
-
1:38
bispecific antibodies, technics use in immunotherapy
-
0:59
discover how amgen’s versatile bispecific t-cell engager (bite®) platform works #cancer #amgen
-
1:14
the car t-cell strategy vs bispecific antibodies
-
1:24:10
webinar: harnessing the power of bispecific antibodies
-
1:30
bispecific antibodies for r/r aggressive b-cell lymphomas
-
23:13
bispecific antibodies in multiple myeloma | dana-farber cancer institute
-
21:32
bispecific antibodies for t‐cell redirection therapy
-
23:52
t cell engager antibodies – focus on hematological malignancies | presented by dr. john kuruvilla